2022 AACR Poster #146: Transcriptome augmentation provides accurate and sensitive quantification of genes associated with the tumor microenvironment


Tumors harbor a complex and dynamic ecosystem of malignant, immune, and stromal cells. While malignant cells dictate much of the tumor biology, there is evidence that the tumor microenvironment (TME) also plays a significant role in disease progression and response to therapy. The role of the immune cells is particularly relevant in immunotherapy, and multiple transcriptome-based biomarkers have shown utility in predicting the efficacy of immune checkpoint blockade. However, little is known about the benefits of enhancing the depth and uniformity of transcriptome sequencing coverage for quantifying the TME cell type composition.